EVP and CFO of Ultragenyx Pharmaceutical Inc.
Shalini Sharp is EVP and CFO of Ultragenyx Pharmaceutical Inc., a publicly traded biotechnology company committed to bringing to market novel products for the treatment of rare genetic diseases primarily affecting pediatric patients. With over 20 years of experience in the life sciences industry, Ms. Sharp leads the finance, corporate communications, corporate strategy, and information technology operations of the company. She is also a member of the boards of directors of the TB Alliance, a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world, as well as three publicly traded oncology biotechnology companies, Array Biopharma, Sutro Biopharma, and Precision Biosciences. Previously, she was CFO and board member of Agenus, a cancer immunology biotechnology company. Prior to that, she held various roles at Elan Corporation plc, an Irish company working on neurological diseases, including chief of staff to the chairman of the board during the company’s restructuring. She was also a management consultant at McKinsey & Company and an investment banker at Goldman Sachs, specializing in life sciences. Ms. Sharp has both a B.A. and an M.B.A. from Harvard University. She has two children who currently attend Black Pine Circle School.